Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$77.93 USD

77.93
3,238,557

-0.68 (-0.87%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $77.93 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Edwards Lifesciences (EW) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Edwards Lifesciences (EW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for December 19th

by Tirthankar Chakraborty

Here are 3 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

Zacks Equity Research

Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Edwards Lifesciences (EW) closed at $235.63 in the latest trading session, marking a -0.96% move from the prior day.

Zacks Equity Research

Here's Why You Should Hold on to Allscripts Stock for Now

by Zacks Equity Research

Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.

Zacks Equity Research

Here's Why You Should Bet on Integer Holdings Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

Zacks Equity Research

Here's Why You Should Invest in Cardinal Health Stock Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.

Zacks Equity Research

NextGen Healthcare Boosts Patient Care With CHC Strategies

by Zacks Equity Research

NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.

Zacks Equity Research

Here's Why You Should Retain NextGen Healthcare for Now

by Zacks Equity Research

NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

Zacks Equity Research

Here's Why You Should Retain Wright Medical Stock For Now

by Zacks Equity Research

Wright Medical (WMGI) is gaining traction from strong international presence and robust product portfolio. However, adverse forex continues to raise concerns.

Zacks Equity Research

Edwards Lifesciences (EW) Plans Strong Long-Term TAVR Growth

by Zacks Equity Research

Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.

Zacks Equity Research

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.

Zacks Equity Research

NuVasive (NUVA) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Zacks Equity Research

Patterson Companies (PDCO) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Patterson Companies' (PDCO) Q2 results benefit from higher revenues, gross margin expansion and solid show by Dental segment.

Zacks Equity Research

What's in the Cards for Cantel Medical (CMD) in Q1 Earnings?

by Zacks Equity Research

Better-than-expected performance at both Medical and Dental segments is likely to have driven Cantel Medical (CMD) in Q1 earnings.

Zacks Equity Research

Here's Why You Should Hold On to HMS Holdings (HMSY) Stock

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services. However, high debt continues to raise concerns.

Zacks Equity Research

Cooper Companies (COO) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Better-than-expected performance at CVI and CSI, and higher revenues are likely to have aided Cooper Companies (COO) in Q4 earnings.

Zacks Equity Research

Edwards Lifesciences (EW) Up 6.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

What's in the Cards for Veeva Systems (VEEV) in Q3 Earnings?

by Zacks Equity Research

Robust product portfolio and higher revenues are likely to have benefited Veeva Systems (VEEV) in third-quarter fiscal 2020 earnings.

Zacks Equity Research

Edwards Lifesciences, Fossil, United Airlines and Boeing highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Edwards Lifesciences, Fossil, United Airlines and Boeing highlighted as Zacks Bull and Bear of the Day

Tracey Ryniec headshot

Bull of the Day: Edwards Lifesciences (EW)

by Tracey Ryniec

This medical innovator is a superstar stock.

Mark Vickery headshot

Top Analyst Reports for Apple, Comcast & NVIDIA

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Comcast Corporation (CMCSA) and NVIDIA Corporation (NVDA).

Zacks Equity Research

Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath

by Zacks Equity Research

Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.

Sanghamitra Saha headshot

Top & Flop ETFs of Last Week

by Sanghamitra Saha

Cocoa ETF was a hot trade last week while cannabis ETF lost the most.

Zacks Equity Research

Haemonetics (HAE) Grows on New Products, Robust Plasma Sales

by Zacks Equity Research

Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.